High-Value Care Every Time: Recommendations From The National Quality Task Force
(7/30, Ayesha D'Avena, Shantanu Agrawal and Kenneth Kizer, Health Affairs Blog) comments “...Consistent with the 2002 NQF National Framework for Healthcare Quality Measurement and Reporting, the Task Force specified the need to capture accurate data at the point of care to improve data veracity and reduce administrative burden. Timely transparency of valid data is necessary for comparative benchmarking and continuous improvement. Data standardization is also necessary to reduce duplicative measures and administrative burden and bolster measure alignment and development. The Task Force validated the need to align stakeholders to a universal, limited set of identical measures, allowing for additional measure sets as necessary to account for geographic and population-specific variation.” Full
Viewpoint: Integrating Personalized Medicine With Population Health Management: The Path Forward
(7/30, David C. Grossman, MD, MPH; Eric B. Larson, MD, MPH; Harold C. Sox, MD, JAMA) comments “...In the near future, genome-wide DNA sequencing will likely become a part of regular medical practice and represents an era of ‘personalized medicine’...However, while personalized medicine may be a key to population health, the way forward will be costly, wasteful, and potentially harmful without the establishment of priorities, adherence to rules of evidence, and the patience to wait for outcomes to unfold over years of observation.” Full
A Military-Civilian Perspective on Real-World Evidence to Support Regulatory Decision Making
(7/29, Todd E. Rasmussen, MD, and Brian J. Young, MBA, Regulatory Focus) reports “...This article summarizes the framework promoting the collection and analysis of real-world data in the healthcare system. The authors emphasize how the US Military Health System used RWD during the Iraq and Afghanistan Wars to achieve historic rates of survival and describe a new era of collaboration between the US Department of Defense and the US Food and Drug Administration. The article reviews the FDA evidentiary standards for medical product approval and gives examples of how RWE can help meet those standards.” Full
Incorporating Value-Based Care Into Oncology
Seymour, Erlene K. MD, et al.
July/August 2020, The Cancer Journal
The Cancer Journal
A Crisis in US Drug Pricing: Consequences for Patients with Neuromuscular Diseases, Physicians, and Society, Part 2
Ted M. Burns, MD, et al.
July 29, 2020, Muscle & Nerve
Evaluation of the Use of Cancer Registry Data for Comparative Effectiveness Research
Abhishek Kumar, MD, MAS; Zachary D. Guss, MD; Patrick T. Courtney, BA, et al.
July 30, 2020, JAMA Network Open
JAMA Network Open
Uterine-Artery Embolization or Myomectomy for Uterine Fibroids
Isaac Manyonda, Ph.D., et al.
July 30, 2020, The New England Journal of Medicine